MyelinWatch EL
← Back to updates
Emerging treatmentsMyelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding

Laboratory and animal research

DITPA / Petratos: early results suggest nerve protection and myelin repair in mice

Worth knowing

Steven Petratos's team reported that daily DITPA by mouth reduced neurological decline, helped myelin-making cells survive, reduced damage to myelin and nerve fibres, and improved related measurements in mice.

What this means for people with MS

This is an active and serious research programme, but there is no publicly registered study in people with MS. Results in mice are not evidence of benefit in people.

What kind of evidence exists?
Early paper not yet independently reviewed • animal model of MS
How reliable is this source?
Preliminary • early paper not yet reviewed by independent scientists

Related study or programme: Petratos / DITPA research →

PreprintRead the source ↗

Related substantive developments

Myelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding

Laboratory and animal research

Blocking fibronectin restored remyelination in experimental models

A PNAS study found that a protein called fibronectin can build up in areas where myelin has been lost. This may trap immature cells that could otherwise become myelin-making cells. Blocking fibronectin improved myelin repair and symptoms in two animal models.

Read the update →Peer-reviewed paper
Emerging treatmentsMyelin repair
Registered study in peopleOngoing, but not accepting participantsNo evidence of benefit in people yet

Phase 3 study that can add or remove treatments

OCTOPUS: the first review of metformin and alpha-lipoic acid is planned for September 2026

The first OCTOPUS review in progressive MS will assess metformin and alpha-lipoic acid. It will look at brain shrinkage on MRI, disability, walking speed and hand function.

Read the update →University / investigator